Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

• James Larkin,
• Jedd Wolchok,
• David F McDermott,
• Michael A Postow,
• Ahmad A Tarhini,
• Michael B Atkins,
• F Stephen Hodi,
• Corey Ritchings,
• Brian Stwalley,
• Andriy Moshyk,
• Meredith M Regan,
• Charlene M Mantia,
• Lillian Werner,
• Sandra Re,
• Wim van Dijck

Affiliations

James Larkin

The Royal Marsden NHS Foundation Trust, London, UK

Jedd Wolchok

Memorial Sloan Kettering Cancer Center, New York, New York, USA

David F McDermott

Harvard Medical School, Boston, Massachusetts, USA

Michael A Postow

Memorial Sloan Kettering Cancer Center, New York, New York, USA

Ahmad A Tarhini

H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

Michael B Atkins

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA

F Stephen Hodi

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Corey Ritchings

Bristol Myers Squibb, Princeton, New Jersey, USA

Brian Stwalley

Bristol Myers Squibb, Princeton, New Jersey, USA

Andriy Moshyk

Bristol Myers Squibb, Princeton, New Jersey, USA

Meredith M Regan

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Charlene M Mantia

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Lillian Werner

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Sandra Re

Bristol Myers Squibb, Princeton, New Jersey, USA

Wim van Dijck

Bristol Myers Squibb, Braine-l’Alleud, Belgium